Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study

Abstract

Prediabetes is often observed in patients with Metabolic Syndrome (MetS) and might be associated with metabolic and inflammatory alterations. Here, we investigated whether the inflammatory molecule osteopontin (OPN) might have a prognostic impact in a cohort of MetS patients (n = 85) with baseline normal glycaemia or impaired fasting glucose (IFG) over one year of recommended pharmacological treatments and Mediterranean diet. Patients were then followed up for 12 months with intermediate evaluation after 6 months. At all time points, anthropometric and clinical data were recorded, alongside with haematological and biochemical profiles, including serum concentrations of OPN. As expected, Mediterranean diet improves glycaemic profile in patients with IFG. Baseline serum OPN failed to be associated with baseline anthropometric or biochemical variables. At baseline, higher levels of OPN were shown in patients with IFG as compared to normal glycaemia. Two distinct subgroups of patients in whom OPN decreased or remained stable/increased at follow‐up were identified. When higher serum OPN levels were observed at baseline, greater reduction was observed at 1‐year follow‐up. Reduction in circulating OPN levels was associated with metabolic improvement in terms of blood pressure, LDL‐c, HDL‐c, and glycaemia. At both univariate and adjusted logistic regression analyses, serum OPN emerged as an independent predictor of glycaemic profile improvement at 1‐year follow‐up (adjOR 1.05 [1.00‐1.10]; P = .041). In conclusion, pharmacological and dietetic interventions improved glycaemic profile in patients with MetS. In particular, glycaemic improvement was demonstrated in patients who also reduce circulating OPN levels. Higher OPN levels at baseline predict normalization of glycaemic profile.

Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives

“…Data have been published that indicate that P1NP concentration can be a marker of liver fibrosis in other chronic liver diseases as well [61,79,80], for e.g., P1NP levels were higher in patients with primary biliary cholangitis than in control subjects [79]. Similarly, patients with alcoholic cirrhosis demonstrated a significantly higher mean serum P1NP content against the control group, and its concentration seemed to increase with the severity of liver damage (i.e., P1NP level was significantly higher in patients with decompensated liver cirrhosis [Child-Pugh class C] vs. the patients with compensated liver cirrhosis [Child-Pugh class A]) [77]. The following factors could possibly account for the strong association between blood P1NP concentration and pronounced liver fibrosis in NAFLD patients: (1) P1NP metabolism occurs in the liver; (2) stellate cells are intrinsically capable of producing this propeptide.…”

“…As a result of adiponectin interaction with its receptor, a temporary dose-dependent increase in the activity of alkaline phosphatase, osteocalcin, and the production of type I collagen are observed. Thus, one can suggest that high levels of adiponectin increase BMD and activate osteoblast differentiation [77].…”

Immunoregulatory Roles of Osteopontin in Diseases

“…In diabetes, OPN levels are correlated with glycemic control [ 83 ]. OPN deficiency increases insulin sensitivity [ 84 ].…”

Lactoferrin, Osteopontin and Lactoferrin–Osteopontin Complex: A Critical Look on Their Role in Perinatal Period and Cardiometabolic Disorders

“… Biological functions of bioactive milk osteopontin. Related references cited in the Figure: ( a: [ 125 , 126 ]; b : [ 127 ]; c : [ 128 ]; d : [ 129 ]; e : [ 130 , 131 , 132 ]; f : [ 133 ]; g : [ 134 ]; h : [ 135 ]; i : [ 136 ]; j : [ 137 ]; k : [ 138 ]; l : [ 139 , 140 ]; m : [ 141 ]; n : [ 142 ]; o : [ 143 ]; p : [ 144 ]; q : [ 145 ]; r : [ 146 ]; s : [ 147 ]; t : [ 148 , 149 ]; u : [ 150 ]). …”